Document Detail

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
MedLine Citation:
PMID:  17654489     Owner:  NLM     Status:  MEDLINE    
CONCLUSIONS: Our results provide new insights into how angiogenesis regulates portal hypertension by demonstrating that the maintenance of increased portal pressure, hyperkinetic circulation, splanchnic neovascularization, and portosystemic collateralization is regulated by VEGF and PDGF in portal hypertensive rats. Importantly, these findings also suggest that an extended antiangiogenic strategy (that is, targeting VEGF/endothelium and PDGF/pericytes) may be a novel approach to the treatment of portal hypertension.
Mercedes Fernandez; Marc Mejias; Ester Garcia-Pras; Raul Mendez; Juan Carlos Garcia-Pagan; Jaime Bosch
Related Documents :
3710429 - Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to s...
11742199 - Portal hypertension due to intrahepatic obstruction in non-hodgkin's lymphoma.
606739 - Accumulation of technetium-99m stannous pyrophosphate in contused myocardium.
559019 - Stability of perceived tension as a function of the menstrual cycle.
19096979 - A modified canine model of portal hypertension with hypersplenism.
8496039 - Animal model of portal hypertension with observations regarding the relationship betwee...
8128849 - Perilymph pressure during hypobaric conditions--cochlear aqueduct obstructed.
3101539 - Single breath end-tidal pco2 measurement during high frequency jet ventilation in criti...
16141379 - Nasal wall compliance in vasomotor rhinitis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  46     ISSN:  0270-9139     ISO Abbreviation:  Hepatology     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-11-05     Completed Date:  2007-11-30     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1208-17     Citation Subset:  IM    
Hepatic Hemodynamic Laboratory, Liver Unit, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Ciberehd, Universitat de Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Models, Animal
Drug Therapy, Combination
Hypertension, Portal / drug therapy,  metabolism,  physiopathology*
Immunosuppressive Agents / therapeutic use
Mesenteric Artery, Superior / physiopathology
Neovascularization, Pathologic / drug therapy,  metabolism*
Piperazines / therapeutic use
Platelet-Derived Growth Factor / antagonists & inhibitors*,  metabolism
Portal Vein / physiopathology
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use
Rats, Sprague-Dawley
Regional Blood Flow / physiology
Signal Transduction / physiology
Sirolimus / therapeutic use
Splanchnic Circulation / physiology*
Vascular Endothelial Growth Factor A / antagonists & inhibitors*,  metabolism
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Piperazines; 0/Platelet-Derived Growth Factor; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/Vascular Endothelial Growth Factor A; 53123-88-9/Sirolimus; BKJ8M8G5HI/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Using standardized survey items with older adults hospitalized for chronic illness.
Next Document:  Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asi...